E-MAIL   PASSWORD Forgot password?New user?

Effectiveness of Biologics in Response/Remission of Crohn’s Disease

Release Date: Jul 01, 2008
Expiration Date: Jun 30, 2009

Download Now | Claim your Credits | E-mail to Colleague

Header

Download Now | Claim your Credits | E-mail to Colleague


In the current environment for the treatment of Crohn’s disease there are 4 available biologic agents that physicians can choose. The choice of which biologic is appropriate for a certain patient requires the physician to consider a number of factors including patient medical history, patient convenience, and the clinical data that support the use of biologic or another. This Pod Pearl will help to clarify these issues and elucidate the data that supports the use of biologics for patients with Crohn’s disease.



Medical Crossfire PodPearlsTM feature brief exchanges between a moderator and faculty members on important topics of interest to the practicing clinician. Pod Pearls CME-certified audio files can be listened to online or downloaded to an MP3 player. This format brings the clinical insights physicians have come to expect from Medical Crossfire to the busy clinician who needs to stay up-to-date on the implications of current knowledge on patient care.


Educational Overview

In the current environment for the treatment of Crohn’s disease there are 4 available biologic agents that physicians can choose. The choice of which biologic is appropriate for a certain patient requires the physician to consider a number of factors including patient medical history, patient convenience, and the clinical data that support the use of biologic or another. This Pod Pearl will help to clarify these issues and elucidate the data that supports the use of biologics for patients with Crohn's disease.


Learning Objectives

Following completion of this activity, participants should be able to:

  • Compare and contrast the current data on biologics for the treatment of Inflammatory Bowel Disease.
  • Identify clinical strategies based on available evidence for optimizing the use of biologic therapies in the treatment of Crohn's disease.


Target Audience

This educational activity is designed for gastroenterologists and other health care professionals interested in or involved with the management of patients with Inflammatory Bowel Disease.



Method of Instruction

Participants should read the learning objectives and listen to the activity in its entirety. After reviewing the activity, print out and mail or fax the evaluation and you will receive a letter of credit awarding AMA PRA Category 1 Credit(s)TM three to four weeks after receipt of the evaluation.

Estimated time to complete this activity as designed is 0.5 hours.



Accreditation Statement

Temple University School of Medicine is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to sponsor Continuing Medical Education for Physicians.



Certification Statement

Temple University School of Medicine designates this educational activity for a maximum of .5 AMA Physician’s Recognition Award Category 1 CreditTM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Temple University School of Medicine is an approved provider of continuing nursing education by the PA State Nurses Association, an accredited approver by the American Nurses Credentialing Center's Commission on Accreditation.



Disclosure Policy

It is the policy of Temple University School of Medicine; The Albert J. Finestone, M.D. Office for Continuing Medical Education to insure balance, independence, objectivity and scientific rigor in all of it’s sponsored or jointly sponsored educational programs. All faculty participating in programs sponsored or jointly sponsored by Temple University School of Medicine are expected to disclose to the program audience any real or apparent conflict (s) of interest related to the content of their presentation(s).

The information presented at this CME program represents the views and opinions of the individual presenters, and does not constitute the opinion or endorsement of, or promotion by, Temple University School of Medicine, Temple University Health System or its affiliates. Reasonable efforts have been taken intending for educational subject matter to be presented in a balanced, unbiased fashion and in compliance with regulatory requirements. However, each program attendee must always use his/her own personal and professional judgment when considering further application of this information, particularly as it may relate to patient diagnostic or treatment decisions including, without limitation, FDA-approved uses and any off-label uses.



Faculty Disclosure Declarations

Marla Dubinsky, MD has received grant/research support from Centocor, UCB Pharma, Abbott Laboratories and Prometheus Labs.

Scott Plevy, MD has been a consultant for Abbott Immunology, Callisto Pharmaceuticals, Centocor, Elan Pharmaceuticals, enGene, Inc., Genentech, Johnson & Johnson, Proctor & Gamble, Schering-Plough, Shire Pharmaceuticals, UCB Pharma. He has received grant/research from Viamet Pharmaceuticals. He has also received royalties from Prometheus Labs.

Stephen B. Hanauer, MD has been a consultant for Abbott Laboratories, Amgen, Bristol Myers Squibb, Centocor, Elan Pharmaceuticals, Genentech, Millenium Pharmaceuticals. He has received grant/research support from Abbott Laboratories, Centocor, Elan Pharmaceuticals, Genentech, and UCB Pharma.


Copyright 2008 Temple University School of Medicine



Planning Committee Disclosures

Temple University School of Medicine:
Arnold Meyer, Ed.D.
Melinda Somasekhar, PhD

No commercial relationships to disclose.

Healthcare First:
Donna Bonura
Andrew Finan
David Lepping

No commercial relationships to disclose.




 
Presented by Presented by Temple University School of Medicine and HealthcareFirst
Supported by This activity is supported by an educational grant from Centocor Ortho Biotech Inc.
Moderator HeaderSTEPHEN B. HANAUER, MD

STEPHEN B. HANAUER, MD

  • Professor of Medicine and Clinical Pharmacology
  • University of Chicago
  • Chicago, Illinois
Panelist HeaderMARLA C. DUBINSKY, MD

MARLA C. DUBINSKY, MD

  • Assistant Professor of Pediatrics
  • David Geffen School of Medicine
  • University of California, Los Angeles
  • Director, Pediatric Inflammatory Bowel Disease Center
  • Los Angeles, California
Panelist HeaderSCOTT E. PLEVY, MD

SCOTT E. PLEVY, MD

  • Associate Professor of Medicine
  • University of North Carolina School of Medicine
  • Division of Gastroenterology and Hepatology
  • Inflammatory Bowel Disease Center
  • Chapel Hill, North Carolina